Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12290424 | 0.87 | NPSR1 (0.41) | ALDH1A1BACE1TDP1KMT2A | |
| SCHEMBL5642127 | 0.85 | BACE1 (0.42) | ALDH1A1FFAR1BACE1 | |
| SCHEMBL9869709 | 0.85 | CASP3 (0.41) | ALDH1A1HDAC2HDAC8HDAC6L3MBTL1 | |
| SCHEMBL31388683 | 0.84 | MEN1 (0.42) | ALDH1A1KEAP1FFAR1TDP1KMT2A | |
| SCHEMBL31388682 | 0.84 | MEN1 (0.42) | ALDH1A1KEAP1FFAR1TDP1KMT2A | |
| SCHEMBL31388685 | 0.83 | ALDH1A1 (0.41) | ALDH1A1KEAP1FFAR1GAAL3MBTL1 | |
| SCHEMBL3945233 | 0.83 | GLA (0.62) | ALDH1A1FFAR1KMT2A | |
| SCHEMBL5639921 | 0.82 | BACE1 (0.61) | FFAR1BACE1HDAC8 | |
| SCHEMBL3951320 | 0.82 | GLA (0.47) | HDAC6KMT2A | |
| SCHEMBL3941852 | 0.78 | MTNR1A (0.44) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250107525-A1 | CARBOXYLIC ACID-DERIVED KETO-DIESTERS AND USES THEREOF | UNIVERSITY OF MISSISSIPPI | 2025-04-03 | — | — | US | disclosed |
| US-20210387960-A1 | NRF2 ACTIVATOR | BIOGEN MA INC. | 2021-12-16 | — | — | US | disclosed |
| WO-2018140738-A1 | NRF 2 ACTIVATOR | BIOGEN MA INC. (US) | 2018-08-02 | — | — | WO | disclosed |
| US-6333336-B1 | GAMMA-AMINOBUTYRIC ACID RECEPTORS AS ANTICONVULSANTS FORMING THE COMPOUND BY AMIDATION | MERCK SHARP & DOHME LTD. (GB) | 2001-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210387960-A1 | NRF2 ACTIVATOR | NFE2L2, NFE2, KEAP1 | ALDH1A1 823/4885KEAP1 3/4885FFAR1 1671/4885 |
| US-20250107525-A1 | CARBOXYLIC ACID-DERIVED KETO-DIESTERS AND USES THEREOF | BCKDK, KYAT1, KYAT3 | ALDH1A1 438/4885KEAP1 1182/4885FFAR1 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.